Accreditation/Credit Designation

Physicians' Education Resource®, LLC, is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Physicians' Education Resource®, LLC, designates this enduring material for a maximum of 2.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Physicians' Education Resource®, LLC, is approved by the California Board of Registered Nursing, Provider #16669 for 2.0 Contact Hours.

Acknowledgment of Commercial Support

This activity is supported by educational grants from Array BioPharma, Inc., Merck Sharp & Dohme Corp., Novartis Pharmaceuticals Corporation, Prometheus Laboratories Inc., and Regeneron and Sanofi Genzyme.

Community Practice Connections™: 15th Annual International Symposium on Melanoma and Other Cutaneous Malignancies®

Release Date: April 30, 2019
Expiration Date: April 30, 2020
Media: Internet - based

Activity Overview

Community Practice Connections™ 15th Annual International Symposium on Melanoma and Other Cutaneous Malignancies® highlights the latest developments in the treatment of melanoma and cutaneous squamous cell carcinoma using the latest treatment strategies. Changes in the understanding of appropriate use of BRAF/MEK inhibitors and PD-1 inhibitors in the metastatic and adjuvant disease setting have created educational gaps among community practitioners who face the continuing challenge of staying up-to-date with developments in the field. In this program, you will hear directly from top experts in melanoma and other cutaneous malignancies on the appropriate sequencing and optimal strategies for adverse event management with recently approved agents. You will gain insights into the use of biomarkers for selection of treatment. Experts discuss the most important findings from key clinical trials and how these findings change treatment practices across cutaneous malignancies so your patients can get the best possible treatments supported by the most recent evidence.

Continuing Medical Education (CME) Activity Table of Contents

  • Module 1: The Importance of Mutational and Biomarker Data Across Cutaneous Malignancies
  • Module 2: Sequencing Therapies in the Adjuvant and Metastatic Settings of Melanoma and Other Cutaneous Malignancies
  • Module 3: Best Practices for Management of Potential Treatment-Related Adverse Events Across Cutaneous Malignancies

Acknowledgement of Commercial Support

This activity is supported by educational grants from Array BioPharma, Inc., Merck Sharp & Dohme Corp., Novartis Pharmaceuticals Corporation, Prometheus Laboratories Inc., and Regeneron and Sanofi Genzyme.

Instructions for This Activity and Receiving Credit

  • You will need to log in to participate in the activity.
  • Each presentation may contain an interactive question(s). You may move forward through the presentation; however, you may not go back to change answers or review audio files/content until you finish the presentation.
  • At the end of the activity, educational content/audio files will be available for your reference.
  • In order to receive a CME/CE certificate, you must complete the activity.
  • Complete the Posttest and pass with a score of 70% or higher, complete the Evaluation, and then click on “Request for Credit.” You may immediately download a CME/CE certificate upon completion of these steps.

Target Audience

This educational activity is directed toward medical oncologists, fellows, surgical oncologists, and radiation oncologists who treat patients with skin and other cutaneous malignancies. Dermatologists, dermatopathologists and pathologists, nurse practitioners, nurses, physician assistants, pharmacists, researchers, and other health care professionals interested in the treatment of melanoma and other cutaneous malignancies will be invited to participate.

Learning Objectives

Upon successful completion of this educational program, you should be better prepared to:

  • Discuss the latest clinical trial evidence on current and emerging treatment strategies across cutaneous malignancies, including regional, immuno-, and targeted therapies
  • Demonstrate the impact of multidisciplinary approaches for the identification and management of treatment-related toxicities in patients with cutaneous malignancies
  • Detail the evolving use of biomarkers and other methods to personalize care across treatment settings for patients with melanoma and other cutaneous malignancies
  • Place recent and emerging trial evidence in the context of changing treatment paradigms in order to optimally sequence therapies in the management of melanoma, basal cell carcinoma, Merkel cell carcinoma, and other cutaneous malignancies

Faculty, Staff, and Planners’ Disclosures

Omid Hamid
Omid Hamid, MD
Chief, Translational Research & Immuno-Oncology
Director, Cutaneous Malignancies, The Angeles Clinic and Research Institute
Director of Experimental Therapeutics, Cedars Sinai Medical Care Foundation
Los Angeles, CA

Disclosures:Grant Research/Support: AstraZeneca, BMS, Celldex, Genentech-Roche, Immuno-core, Incyte, Merck, Merck Serono, MedImmune, Novartis, Pfizer, Rinat; Consultant: Amgen, BMS, Genentech Roche, Merck, Novartis; Speakers Bureau: Amgen, Array BioPhar-ma, BMS, Genentech Roche, Novartis

Jeffrey S. Weber
Jeffrey S. Weber, MD, PhD
Deputy Director
Laura and Isaac Perlmutter Cancer Center
Professor of Medicine
NYU Langone Medical Center
New York, NY

Disclosures: Grant./Research Support: BMS, Genentech, GSK, Incyte, Merck, Moffitt; Consultant: AstraZeneca, BMS, Genentech, GSK, Incyte, Medivation, Merck; Shareholder: Altor, Biond, cCAM, Celldex, CytomX; Other: Named on a patent held by Moffitt that relates to a predictive marker for ipilimumab

Ryan J. Sullivan
Ryan J. Sullivan, MD
Medical Oncologist
Assistant Professor of Medicine
Harvard Medical School
Director, Translational Research, Center for Melanoma
Massachusetts General Hospital Cancer Center
Principal Investigator
Dana-Farber Harvard Cancer Center
Boston, MA

Disclosures: Grant/Research Support: Amgen, Merck; Consultant: Amgen, Compugen, Genentech, Merck, Novartis, Replimune, Syndax

The staff of Physicians' Education Resource®, LLC (PER®), have no relevant financial relationships with commercial interests to disclose.

Disclosure Policy and Resolution of Conflicts of Interest (COI)

As a sponsor accredited by the ACCME, it is the policy of PER® to ensure fair balance, independence, objectivity, and scientific rigor in all of its CME/CE activities. In compliance with ACCME guidelines, PER® requires everyone who is in a position to control the content of a CME/CE activity to disclose all relevant financial relationships with commercial interests. The ACCME defines “relevant financial relationships” as financial relationships in any amount occurring within the past 12 months that creates a COI.

Additionally, PER® is required by ACCME to resolve all COI. PER® has identified and resolved all COI prior to the start of this activity by using a multistep process

Off-Label Disclosure and Disclaimer

This CME/CE activity may or may not discuss investigational, unapproved, or off-label use of drugs. Participants are advised to consult prescribing information for any products discussed. The information provided in this CME/CE activity is for continuing medical and nursing education purposes only, and is not meant to substitute for the independent clinical judgment of a physician relative to diagnostic or treatment options for a specific patient’s medical condition.

The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER®.

Login or Register to Start Activity

Please use the form below to Register or Log In to begin Activity.

*Required Fields
Calendar of Events
Filter By